The Future of Alzheimer's Treatment

3min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

L'acannamab, marketed in the United States as l'acambi, makes for a tough treatment regime. It has to be infused through a vein by a nursing professional. Because it can cause potentially life-threatening brain swelling and bleeds, people taking it have to be monitored regularly. A similar antibody, Adju-cannamab was approved by the US Food and Drug Administration in 2021,. but the decision generated controversy because the drug's clinical trial had not shown an ambiguous benefit.

Last year, researchers announced that the Alzheimer’s drug lecanemab lowered the amount of amyloid protein plaques associated with the disease in the brains of participants in a clinical trial, and slowed their cognitive decline.

Now, researchers are looking to drug combinations, vaccines and gene therapy to tackle different stages of the disease, as they forge the next generation of treatments for the condition.

This is an audio version of our Feature: Conquering Alzheimer’s: a look at the therapies of the future

Hosted on Acast. See acast.com/privacy for more information.